MedTrace Logo

Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes

NCT01475461 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 345

Last updated 2017-01-31

Study results available
· View outcomes & findings →

Summary

B1621007 is designed to study the safety and efficacy of PF-04937319 in patients with type 2 diabetes

Conditions

Interventions

DRUG

Placebo

double-dummy placebo tablets administered once-daily for 84-days

DRUG

PF-04937319 - 3mg

PF-04937319 3mg administered as tablets once-daily for 84-days

DRUG

PF-04937319 - 20mg

PF-04937319 20mg administered as tablets once-daily for 84-days

DRUG

PF-04937319 - 50mg

PF-04937319 50mg administered as tablets once-daily for 84-days

DRUG

PF-04937319 - 100mg

PF-04937319 100mg administered as tablets once-daily for 84-days

DRUG

Sitagliptin - 100mg

Sitagliptin 100mg administered as tablets once-daily for 84-days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States
  • Hungary
  • India
  • Philippines
  • Romania
  • Slovakia
  • South Africa
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01475461 on ClinicalTrials.gov